Detection of lipid oxidising abzymes in samples
AssigneeCambridge Theranostics Ltd.
InventorIvan PETYAEV
Life of this patent
Estimating the term…
Abstract
This invention relates to the finding that lipid oxidising abzymes damage Chlamydia antigens in a sample and the extent of damage provides a measure of the level or activity of the abzymes in the sample. Lipid oxidising abzymes may be measured or detected, for example, by abrogating or abolishing abzyme mediated lipid oxidation activity in a sample, and determining the binding of antibodies in the sample to a Chlamydia antigen relative to controls. Such methods may be useful in the assessment of cardiovascular conditions.
Claims32
A method of measuring abzyme levels in a sample comprising;
- abolishing abzyme mediated lipid oxidation in said sample, and
- determining the binding of antibodies in the sample to a Chlamydia antigen,
- wherein an increase in binding in the treated sample relative to controls is indicative of the presence or level of abzymes in the sample.
A method of screening for an abzyme inhibitor comprising;
- determining the binding of antibodies in a sample to a Chlamydia antigen,
- treating the sample with a test compound and;
- determining the binding of antibodies in the treated sample to a Chlamydia antigen,
- an increase the binding of the treated sample relative to the untreated sample being indicative that the compound is an abzyme inhibitor.
Dependencies are inferred from the claim text.